Record Q2 volume and revenue growth exceeded guidance, with profitability achieved ahead of schedule. Expanded payer coverage and operational improvements set the stage for significant collection rate and revenue gains in 2027.Based on GeneDx Holdings Corp. [WGS] Q2 2026 Audio Transcript — Aug. 3 2…
Revenue grew 11% year-over-year to $114.4 million in Q2 2026, driven by a 32% increase in exome and genome test volumes, but higher operating expenses and a $31.3 million impairment charge led to a net loss of $17.7 million. Adjusted net income was $0.4 million, and the company ended the quarter wi…
Q2 2026 saw 32% year-over-year growth in exome and genome test volumes and 17% revenue growth, with adjusted gross margin steady at 70%. Expansion into new markets and payer coverage, plus a strengthened cash position from a Blackstone transaction, support a positive outlook.Original document: Gene…
Key Dates and Disclosure Events GeneDx Shareholders Need to Know: From $51 Million Acquisition Promise to $31.2 Million Write-Off in Just 12 MonthsNEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt alerts investors in GeneDx Holdings Corp. (NASDAQ:WGS) of a pending securities class action. April 16…
SAN FRANCISCO, July 27, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GeneDx Holdings Corp. (NASDAQ:WGS) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses contact the firm now. The upcoming lead…
GeneDx Stock Plunged 49% After May 2026 Disclosure Revealed $31.2 Million Fabric Genomics Write-Off and $65 Million Revenue Guidance Cut, Erasing Billions in Shareholder ValueNEW YORK, July 23, 2026 /PRNewswire/ -- SueWallSt notifies investors in GeneDx Holdings Corp. (NASDAQ:WGS) that a class acti…
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026. Management will host a conference call that day to d…
SAN DIEGO, July 15, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April 16, 2025 and May 4, 2026, all dates inclusive (the "Class Period"), have until Monday, August 3, 2026 to seek appointm…
SAN FRANCISCO, July 7, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ:WGS) and its executives, alleging defendants misled investors about the Fabric Genomics…
